Joe Eazor, President and CEOClario is a clinical trial data management company that fuses science and technology to deliver best-in-class evidence across clinical trial models. Led by science and technology thought leaders, visionaries, and master clinical trial management experts, the company diligently supports regulatory compliance across 120 countries. “What excites me most is that we’re bringing an often-overlooked part of the clinical trial process to the forefront. Most people don’t realize the impact clinical evidence has on regulatory approval and how it accelerates approval and opens investigators’ eyes to medicine uses. The checks and balances we have in place ensure the data quality to the regulator. Clario specializes in generating the richest evidence, empowering partners and ultimately, transforming lives,” says Joe Eazor, President and CEO of Clario.
Emerging from the merger of ERT and Bioclinica in April 2021, Clario holds nearly 50 years of experience in clinical data management. The company blends ERT’s specializations in cardiac safety, respiratory, eCOA, and precision motion with Bioclinica’s imaging, eClinical software, and drug safety solutions to enrich the trial processes. It has successfully executed over 19,000 clinical trials to date and is committed to simplifying trial experiences and unlocking the best clinical evidence through hybrid, decentralized, and site-based trials. With its exemplary Trial AnywhereTM model, the company empowers customers to conduct clinical trials anywhere—in patients’ homes, local facilities, through a home healthcare provider, or on-site.
The factors that give Clario an edge in the market can be distinguished into four key parts— deep scientific expertise, size and scale, broadest endpoint technology platform, and last but not least, purpose. With in-depth scientific knowledge, Clario has been driving decentralized clinical trials in over 200 therapeutic areas. With its sheer scale and size, the company can conduct large trials worldwide in more than 100 languages, providing a comprehensive look into how medicines, medical devices, and therapies perform in diverse environments, cultures, and ethnicities. Furthermore, being equipped with a broad technology platform, Clario simplifies clinical trial experiences and operations and reduces the need for more patients, makes the trial cost-effective, and accelerates timelines to a great extent. The company continuously invests in AI technologies to perform faster and provide more accurate clinical reviews through automation, individualize patient engagement at scale for higher compliance, apply algorithms to detect quality issues or disease progression, and other innovations to enhance clinical trials. For instance, Clario has recently designed and launched a handheld medical device that allows patients to test their lung functions at home. The device collects, stores, and transmits the clinical data electronically and constantly loops real-time data to healthcare providers, helping them recognize if a patient is exhaling properly or not.
Our purpose is clear – we transform lives by unlocking better evidence
For the road ahead, Clario is focused on continuing its quest to improve and enhance the way it does clinical trials. The company is driving its investments towards adopting the latest technologies to better the data quality, speed, and clinical trial experience. Clario is also aiming to offer sites and sponsors further trial options, enable patient choice, and build diversity within clinical trial environments to improve health equity. “Clario is much more than the merger of two companies. Through our technology platform, we have combined decades of scientific expertise and unrivaled global scale to expedite the clinical trial process, simplify its experiences and unlock composite endpoints. Our purpose is clear – we transform lives by unlocking better evidence,” concludes Eazor.
